More recently, the phase III QuANTUM-First trial randomized 539 patients ages 18–75 with FLT3-ITD mutated AML to induction and consolidation chemotherapy plus quizartinib vs placebo; median overall survival was superior in the quizartinib arm (31.9 vs 15.1 months, p = 0.032) [28]. Here, FLT3 is linked to acute myeloid leukemia.